Veda Giri, MD

Genetics; Prostate

• Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and PreventionSeibert T, Garraway I, Plym A, Mahal B, Giri V, Jacobs M, Cheng H, Loeb S, Helfand B, Eeles R, Morgan T. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. European Urology 2023, 83: 241-248. PMID: 36609003, DOI: 10.1016/j.eururo.2022.12.021.
• Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.Giri V, Keith S, Cheng H, Leader A, Gross L, Sanchez Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Loeb S. Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Journal Of Clinical Oncology 2023, 41: 10598-10598. DOI: 10.1200/jco.2023.41.16_suppl.10598.
• A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomesRitch E, Herberts C, Warner E, Ng S, Kwan E, Bacon J, Bernales C, Schönlau E, Fonseca N, Giri V, Maurice-Dror C, Vandekerkhove G, Jones S, Chi K, Wyatt A. A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. Npj Precision Oncology 2023, 7: 27. PMID: 36914848, PMCID: PMC10011564, DOI: 10.1038/s41698-023-00366-z.
• Factors related to men’s experience with prostate cancer germline testing.Giri V, Gross L, Hartman R, Leader A, Whang Y, Couvillon A, Cheng H, Paller C, Loeb S, Karsh L, Friedman S, Beer T, Sokolova A, Keith S. Factors related to men’s experience with prostate cancer germline testing. Journal Of Clinical Oncology 2023, 41: 128-128. DOI: 10.1200/jco.2023.41.6_suppl.128.
• Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI).Couvillon A, Turkbey B, Choyke P, Lee-Wisdom K, McKinney Y, Sidlow R, Mullane M, Giri V, Morgan T, Cheng H, Merino M, Figg W, Pinto P, Dahut W, Karzai F. Inherited risk for prostate cancer (PCa): Following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI). Journal Of Clinical Oncology 2023, 41: 390-390. DOI: 10.1200/jco.2023.41.6_suppl.390.
• Usefulness of podcasts to provide public education on prostate cancer geneticsLoeb S, Sanchez Nolasco T, Siu K, Byrne N, Giri V. Usefulness of podcasts to provide public education on prostate cancer genetics. Prostate Cancer And Prostatic Diseases 2023, 26: 772-777. PMID: 36681741, DOI: 10.1038/s41391-023-00648-4.
• ASCO Living Guidelines: The Next FrontierGiri V, Oliver T, Rumble R, Friedberg J, Miller K, Geisel R. ASCO Living Guidelines: The Next Frontier. Journal Of Clinical Oncology 2022, 41: 955-957. PMID: 36534929, DOI: 10.1200/jco.22.02344.
• Reply to X. Luo et alGiri V, Oliver T, Rumble R, Geisel R. Reply to X. Luo et al. Journal Of Clinical Oncology 2022, 41: 1150-1151. PMID: 36315930, DOI: 10.1200/jco.22.02126.
• Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian CancerThakker S, Loeb S, Giri V, Bjurlin M, Matulewicz R. Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer. Urology Practice 2022, 10: 26-32. PMID: 37103438, DOI: 10.1097/upj.0000000000000352.
• Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for familiesLeader A, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri V. Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families. Journal Of Community Genetics 2022, 13: 547-556. PMID: 35869324, PMCID: PMC9681950, DOI: 10.1007/s12687-022-00603-1.
• Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testingLoeb S, Cheng H, Leader A, Gross L, Nolasco T, Byrne N, Wise D, Hollifield L, Brown L, Slater E, Pieczonka C, Gomella L, Kelly W, Trabulsi E, Handley N, Lallas C, Chandrasekar T, Mille P, Mann M, Mark J, Brown G, Chopra S, Wasserman J, Phillips J, Somers P, Giri V. Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Contemporary Clinical Trials 2022, 119: 106821. PMID: 35710085, DOI: 10.1016/j.cct.2022.106821.
• Patient-reported outcomes among males undergoing prostate cancer germline testing: Interim results from the Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS) Registry.Giri V, Hartman R, Gross L, Keith S. Patient-reported outcomes among males undergoing prostate cancer germline testing: Interim results from the Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS) Registry. Journal Of Clinical Oncology 2022, 40: 10595-10595. DOI: 10.1200/jco.2022.40.16_suppl.10595.
• MP09-16 QUALITY OF INFORMATION IN SPANISH ON BRCA AND GENETIC TESTING IN PROSTATE CANCER ON YOUTUBEFriedman B, Pineault K, Nolasco T, Borno H, Giri V, Loeb S. MP09-16 QUALITY OF INFORMATION IN SPANISH ON BRCA AND GENETIC TESTING IN PROSTATE CANCER ON YOUTUBE. Journal Of Urology 2022, 207: e142. DOI: 10.1097/ju.0000000000002531.16.
• PD13-03 LACK OF AWARENESS AND UNDERUTILIZATION OF GENETIC TESTING IN PROSTATE CANCERThakker S, Loeb S, Giri V, Matulewicz R. PD13-03 LACK OF AWARENESS AND UNDERUTILIZATION OF GENETIC TESTING IN PROSTATE CANCER. Journal Of Urology 2022, 207: e251. DOI: 10.1097/ju.0000000000002545.03.
• Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic TestingGiri V, Hartman R, Pritzlaff M, Horton C, Keith S. Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing. JCO Precision Oncology 2022, 6: e2200234. PMID: 35666082, PMCID: PMC9200399, DOI: 10.1200/po.22.00234.
• Guidelines on Germline Testing for Urologic Tumor SyndromesGomella P, Mark J, Giri V, Kelly W, Gomella L. Guidelines on Germline Testing for Urologic Tumor Syndromes. European Urology Focus 2022, 8: 670-673. PMID: 35803854, DOI: 10.1016/j.euf.2022.06.010.
• Germline testing and genetic counselling in prostate cancerRusso J, Giri V. Germline testing and genetic counselling in prostate cancer. Nature Reviews Urology 2022, 19: 331-343. PMID: 35449224, PMCID: PMC9022414, DOI: 10.1038/s41585-022-00580-7.
• Genetic testing in prostate cancer management: Considerations informing primary careGiri V, Morgan T, Morris D, Berchuck J, Hyatt C, Taplin M. Genetic testing in prostate cancer management: Considerations informing primary care. CA A Cancer Journal For Clinicians 2022, 72: 360-371. PMID: 35201622, DOI: 10.3322/caac.21720.
• Virtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing: The ENGAGEMENT study.Giri V, Gross L, Cheng H, Russo J, Paller C, Johnson J, Weg E, Loeb S. Virtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing: The ENGAGEMENT study. Journal Of Clinical Oncology 2022, 40: 184-184. DOI: 10.1200/jco.2022.40.6_suppl.184.
• Prevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study.Giri V, Gross L, Russo J, Shimada A, McNair C, Kelly W, Gomella L. Prevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study. Journal Of Clinical Oncology 2022, 40: 188-188. DOI: 10.1200/jco.2022.40.6_suppl.188.
• When to use germline genetic testing in prostate cancer.Giri V. When to use germline genetic testing in prostate cancer. Clinical Advances In Hematology And Oncology 2022, 20: 78-81. PMID: 35120087.
• Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical PracticeGiri V, Walker A, Gross L, Trabulsi E, Lallas C, Kelly W, Gomella L, Fischer C, Loeb S. Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice. Clinical Genitourinary Cancer 2021, 20: e104-e113. PMID: 35012874, DOI: 10.1016/j.clgc.2021.11.009.
• Testing a Prostate Cancer Educational Intervention in High-Burden NeighborhoodsZeigler-Johnson C, Madsen R, Keith S, Glanz K, Quinn A, Giri V, Bowen E, Sauls D, Leader A. Testing a Prostate Cancer Educational Intervention in High-Burden Neighborhoods. Journal Of Racial And Ethnic Health Disparities 2021, 9: 2477-2484. PMID: 34748171, PMCID: PMC9973384, DOI: 10.1007/s40615-021-01183-5.
• Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine.Giri V, Shimada A, Leader A. Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine. JCO Precision Oncology 2021, 5: 1699-1708. PMID: 34778693, PMCID: PMC8585288, DOI: 10.1200/po.21.00231.
• Adopting Consensus Terms for Testing in Precision MedicineMartin N, Tepper J, Giri V, Stinchcombe T, Cheng H, Javle M, Konnick E. Adopting Consensus Terms for Testing in Precision Medicine. JCO Precision Oncology 2021, 5: 1563-1567. PMID: 34651094, PMCID: PMC8509918, DOI: 10.1200/po.21.00027.
• Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape AnalysisLoeb S, Massey P, Leader A, Thakker S, Falge E, Taneja S, Byrne N, Rose M, Joy M, Walter D, Katz M, Wong R, Selvan P, Keith S, Giri V. Gaps in Public Awareness About BRCA and Genetic Testing in Prostate Cancer: Social Media Landscape Analysis. JMIR Cancer 2021, 7: e27063. PMID: 34542414, PMCID: PMC8550715, DOI: 10.2196/27063.
• Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice NeedsRusso J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly W, Calvaresi A, Handley N, Hirsch I, Izes J, Lallas C, Mann M, Mark J, Mille P, Preate D, Trabulsi E, Tsang M, Chandrasekar T, Weiner P, Gomella L, Giri V. Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs. JCO Precision Oncology 2021, 5: 1377-1386. PMID: 34589662, PMCID: PMC8462590, DOI: 10.1200/po.21.00238.
• Prostate Cancer Genetics: Changing the Paradigm of CareGomella L, Giri V. Prostate Cancer Genetics: Changing the Paradigm of Care. Urologic Clinics Of North America 2021, 48: i. DOI: 10.1016/s0094-0143(21)01845-0.
• Prostate Cancer Genetics: Changing the Paradigm of CareGomella L, Giri V. Prostate Cancer Genetics: Changing the Paradigm of Care. Urologic Clinics Of North America 2021, 48: xiii-xiv. PMID: 34210497, DOI: 10.1016/j.ucl.2021.06.001.
• B2B: Prostate CancerLoeb S, Black P, Wyatt A, Nyame Y, Shore N, Tilki D, Castro E, Cooperberg M, Giri V, Ribal M, Lughezzani G, Sánchez-Salas R, Moore C, Rastinehad A, Kerkmeijer L, Ahmed H, Akamatsu S, de la Taille A, Gleave M, Tanguay S. B2B: Prostate Cancer. Société Internationale D’Urologie Journal 2021, 2: s30-s50. DOI: 10.48083/zjlz6285.
• Abstract 2605: A natural history study of men with high-risk genetics for prostate cancer (PCa) using multiparametric MRI (mpMRI)Karzai F, Couvillon A, McKinney Y, Lee-Wisdom K, Choyke P, Giri V, Morgan T, Cheng H, Merino M, Pinto P, Turkbey B, Dahut W. Abstract 2605: A natural history study of men with high-risk genetics for prostate cancer (PCa) using multiparametric MRI (mpMRI). Cancer Research 2021, 81: 2605-2605. DOI: 10.1158/1538-7445.am2021-2605.
• Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer CareMark J, McDougall C, Giri V. Genetic Testing Guidelines and Education of Health Care Providers Involved in Prostate Cancer Care. Urologic Clinics Of North America 2021, 48: 311-322. PMID: 34210487, DOI: 10.1016/j.ucl.2021.03.003.
• Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine.Peters C, Turner C, Chesnut G, Giri V, Gomella L, Shriver C, Dobi A. Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine. Canadian Journal Of Urology 2021, 28: 10659-10667. PMID: 34129457.
• Barriers and facilitators of germline genetic evaluation for prostate cancerLoeb S, Li R, Nolasco T, Byrne N, Cheng H, Becker D, Leader A, Giri V. Barriers and facilitators of germline genetic evaluation for prostate cancer. The Prostate 2021, 81: 754-764. PMID: 34057231, DOI: 10.1002/pros.24172.
• Barriers and facilitators of germline genetic evaluation for prostate cancer.Loeb S, Li R, Sanchez Nolasco T, Byrne N, Cheng H, Leader A, Giri V. Barriers and facilitators of germline genetic evaluation for prostate cancer. Journal Of Clinical Oncology 2021, 39: 28-28. DOI: 10.1200/jco.2021.39.6_suppl.28.
• Clinical Implications of Germline Testing in Newly Diagnosed Prostate CancerLoeb S, Giri V. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer. European Urology Oncology 2020, 4: 1-9. PMID: 33390340, DOI: 10.1016/j.euo.2020.11.011.
• Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation✰,✰✰Loeb S, Byrne N, Walter D, Makarov D, Wise D, Becker D, Giri V. Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation✰,✰✰. Cancer Treatment And Research Communications 2020, 25: 100212. PMID: 33091732, DOI: 10.1016/j.ctarc.2020.100212.
• Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.Szymaniak BM, Facchini LA, Giri VN, Antonarakis ES, Beer TM, Carlo MI, Danila DC, Dhawan M, George D, Graff JN, Gupta S, Heath E, Higano CS, Liu G, Molina AM, Paller CJ, Patnaik A, Petrylak DP, Reichert Z, Rettig MB, Ryan CJ, Taplin ME, Vinson J, Whang YE, Morgans AK, Cheng HH, McKay RR. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. JCO Oncology Practice 2020, 16: 811-819. PMID: 32986533, PMCID: PMC7735040, DOI: 10.1200/op.20.00431.
• Physical activity assessment among men undergoing genetic counseling for inherited prostate cancer: a teachable moment for improved survivorshipBruneau M, Milliron B, Sinclair E, Obeid E, Gross L, Bealin L, Smaltz C, Butryn M, Giri V. Physical activity assessment among men undergoing genetic counseling for inherited prostate cancer: a teachable moment for improved survivorship. Supportive Care In Cancer 2020, 29: 2145-2151. PMID: 32876733, PMCID: PMC7897228, DOI: 10.1007/s00520-020-05667-8.
• The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancerLynch S, Handorf E, Sorice K, Blackman E, Bealin L, Giri V, Obeid E, Ragin C, Daly M. The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer. PLOS ONE 2020, 15: e0237332. PMID: 32790761, PMCID: PMC7425919, DOI: 10.1371/journal.pone.0237332.
• Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal Of Clinical Oncology 2020, 38: 2798-2811. PMID: 32516092, PMCID: PMC7430215, DOI: 10.1200/jco.20.00046.
• Neuroendocrine Tumors Are Enriched in Cowden Syndrome.Greidinger A, Miller-Samuel S, Giri V, Woo M, Akumalla S, Zeigler-Johnson C, Keith S, Silver D. Neuroendocrine Tumors Are Enriched in Cowden Syndrome. JCO Precision Oncology 2020, 4: 551-556. PMID: 32923874, PMCID: PMC7446357, DOI: 10.1200/po.19.00241.
• Abstract A028: Exploring Asian Indian and Pakistani views about cancer and participation in research: An evaluation of a culturally tailored educational interventionGiri V, Selvan P, Mohanty S, Lum R, Serrao S, Leader A. Abstract A028: Exploring Asian Indian and Pakistani views about cancer and participation in research: An evaluation of a culturally tailored educational intervention. Cancer Epidemiology Biomarkers & Prevention 2020, 29: a028-a028. DOI: 10.1158/1538-7755.disp18-a028.
• Cancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice.Giri V, Hyatt C, Leader A. Cancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice. Journal Of Urology 2020, 204: 1116-1118. PMID: 32926644, DOI: 10.1097/ju.0000000000001150.
• Video vs. in-person genetic counseling for men considering germline prostate cancer testing: A patient-choice study.Giri V, Bowler N, Hegarty S, Gross L, Hyatt C, Kelly W, Gomella L. Video vs. in-person genetic counseling for men considering germline prostate cancer testing: A patient-choice study. Journal Of Clinical Oncology 2020, 38: 1577-1577. DOI: 10.1200/jco.2020.38.15_suppl.1577.
• Exploring African American males' attitudes towards genetic testing for prostate cancer risk.Leader A, Fortune T, Weddington P, Crumpler N, Giri V. Exploring African American males' attitudes towards genetic testing for prostate cancer risk. Journal Of Clinical Oncology 2020, 38: e13552-e13552. DOI: 10.1200/jco.2020.38.15_suppl.e13552.
• Hereditary Prostate CancerGiri V, Beebe-Dimmer J, Cooney K. Hereditary Prostate Cancer. 2020, 283-292. DOI: 10.1201/9781351187435-33.
• Physical activity assessment among men undergoing genetic counseling for inherited prostate cancer: A teachable moment.Giri V, Milliron B, Sinclair E, Obeid E, Smaltz C, Butryn M, Bruneau M. Physical activity assessment among men undergoing genetic counseling for inherited prostate cancer: A teachable moment. Journal Of Clinical Oncology 2020, 38: 360-360. DOI: 10.1200/jco.2020.38.6_suppl.360.
• Introduction to the 2019 Philadelphia Prostate Cancer Consensus Program: 'Implementation of Genetic Testing for Inherited Prostate Cancer'.Gomella L, Knudsen K, Giri V. Introduction to the 2019 Philadelphia Prostate Cancer Consensus Program: 'Implementation of Genetic Testing for Inherited Prostate Cancer'. Canadian Journal Of Urology 2019, 26: 1-4. PMID: 31629412.
• Genetic education and practice considerations of non-genetic providers.Giri V. Genetic education and practice considerations of non-genetic providers. Canadian Journal Of Urology 2019, 26: 44-45. PMID: 31629430.
• Exploring Asian Indian views about cancer and participation in cancer research: an evaluation of a culturally tailored educational interventionGiri V, Selvan P, Mohanty S, Lum R, Serrao S, Leader A. Exploring Asian Indian views about cancer and participation in cancer research: an evaluation of a culturally tailored educational intervention. Journal Of Community Genetics 2019, 11: 193-203. PMID: 31522341, PMCID: PMC7062964, DOI: 10.1007/s12687-019-00436-5.
• Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1Sannai M, Doneddu V, Giri V, Seeholzer S, Nicolas E, Yip S, Bassi M, Mancuso P, Cortellino S, Cigliano A, Lurie R, Ding H, Chernoff J, Sobol R, Yen T, Bagella L, Bellacosa A. Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1. DNA Repair 2019, 82: 102687. PMID: 31476572, PMCID: PMC6785017, DOI: 10.1016/j.dnarep.2019.102687.
• Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for MenChandrasekar T, Gross L, Gomella L, Hegarty S, Leong J, Giri V. Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men. European Urology Oncology 2019, 3: 291-297. PMID: 31278035, DOI: 10.1016/j.euo.2019.06.010.
• Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumPaller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN, Group P. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer 2019, 17: 275-282.e1. PMID: 31171481, PMCID: PMC6662206, DOI: 10.1016/j.clgc.2019.04.013.
• Germline Testing for Men With Prostate Cancer: Navigating an Expanding New World of Genetic Evaluation for Precision Therapy and Precision ManagementGiri V, Hyatt C, Gomella L. Germline Testing for Men With Prostate Cancer: Navigating an Expanding New World of Genetic Evaluation for Precision Therapy and Precision Management. Journal Of Clinical Oncology 2019, 37: jco.18.02181. PMID: 30978156, DOI: 10.1200/jco.18.02181.
• MP41-04 CASCADE TESTING OF MEN WITH PROSTATE CANCER IN FAMILIES WITH A SPECTRUM OF INHERITED CANCERS: IMPORTANCE OF ATTENTION TO RACEChandrasekar* T, Leong J, Gross L, Hegary S, Gomella L, Giri V. MP41-04 CASCADE TESTING OF MEN WITH PROSTATE CANCER IN FAMILIES WITH A SPECTRUM OF INHERITED CANCERS: IMPORTANCE OF ATTENTION TO RACE. Journal Of Urology 2019, 201 DOI: 10.1097/01.ju.0000556117.44879.21.
• Diet assessment among men undergoing genetic counseling and genetic testing for inherited prostate cancer: Exploring a teachable moment to support diet interventionMilliron B, Bruneau M, Obeid E, Gross L, Bealin L, Smaltz C, Giri V. Diet assessment among men undergoing genetic counseling and genetic testing for inherited prostate cancer: Exploring a teachable moment to support diet intervention. The Prostate 2019, 79: 778-783. PMID: 30905089, PMCID: PMC8283914, DOI: 10.1002/pros.23783.
• Real-World Insights Into Germline Genetic Testing for Prostate CancerGiri V. Real-World Insights Into Germline Genetic Testing for Prostate Cancer. Oncology Times 2019, 41: 12,22-22. DOI: 10.1097/01.cot.0000554514.89621.ad.
• Cascade testing of men with prostate cancer in families with a spectrum of inherited cancers: Importance of attention to race.Giri V, Chandrasekar T, Hegarty S, Gross L, Leong J, Gomella L. Cascade testing of men with prostate cancer in families with a spectrum of inherited cancers: Importance of attention to race. Journal Of Clinical Oncology 2019, 37: 75-75. DOI: 10.1200/jco.2019.37.7_suppl.75.
• Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testingGiri V, Hegarty S, Hyatt C, O'Leary E, Garcia J, Knudsen K, Kelly W, Gomella L. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. The Prostate 2018, 79: 333-339. PMID: 30450585, DOI: 10.1002/pros.23739.
• Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.Carlo M, Giri V, Paller C, Abida W, Alumkal J, Beer T, Beltran H, George D, Heath E, Higano C, McKay R, Morgans A, Patnaik A, Ryan C, Schaeffer E, Stadler W, Taplin M, Kauff N, Vinson J, Antonarakis E, Cheng H. Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precision Oncology 2018, 2018: 1-14. PMID: 30761386, PMCID: PMC6370313, DOI: 10.1200/po.18.00060.
• Nutrition assessment among men undergoing genetic counseling for inherited prostate cancer: A teachable moment.Giri V, Bruneau M, Obeid E, Smaltz C, Milliron B. Nutrition assessment among men undergoing genetic counseling for inherited prostate cancer: A teachable moment. Journal Of Clinical Oncology 2018, 36: 1519-1519. DOI: 10.1200/jco.2018.36.15_suppl.1519.
• Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counselingGiri V, Obeid E, Hegarty S, Gross L, Bealin L, Hyatt C, Fang C, Leader A. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. The Prostate 2018, 78: 879-888. PMID: 29655297, PMCID: PMC6047906, DOI: 10.1002/pros.23535.
• The Frequency of CHEK2 variant p.Ile157Thr in Men with Prostate Cancer: Towards Expanded Genetic TestingAgubokwu N, Giri V. The Frequency of CHEK2 variant p.Ile157Thr in Men with Prostate Cancer: Towards Expanded Genetic Testing. The FASEB Journal 2018, 32: 532.9-532.9. DOI: 10.1096/fasebj.2018.32.1_supplement.532.9.
• MP51-08 PRELIMINARY EXPERIENCE WITH COMPREHENSIVE GENOMIC PROFILING OF GENITOURINARY TUMORS; A TOOL TO DIRECT CLINICAL DECISIONS?Mark J, Kucherov V, Den R, Dicker A, Giri V, Godwin J, Hoffman-Censits J, Lallas C, Mann M, McCue P, Trabulsi E, Knudsen K, Kelly W, Gomella L. MP51-08 PRELIMINARY EXPERIENCE WITH COMPREHENSIVE GENOMIC PROFILING OF GENITOURINARY TUMORS; A TOOL TO DIRECT CLINICAL DECISIONS? Journal Of Urology 2018, 199: e687. DOI: 10.1016/j.juro.2018.02.1639.
• Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal Of Clinical Oncology 2017, 36: jco.2017.74.117. PMID: 29236593, PMCID: PMC6075860, DOI: 10.1200/jco.2017.74.1173.
• The Role of Genetic Counseling in Familial and Sporadic Cancer: Considerations, Challenges, and Collaboration.Giri V, Yurgelun M, Robson M. The Role of Genetic Counseling in Familial and Sporadic Cancer: Considerations, Challenges, and Collaboration. Annals Of Internal Medicine 2017, 167: 884-885. PMID: 29086794, DOI: 10.7326/m17-2512.
• Exploring Asian Indian and Pakistani views about cancer and participation in cancer genetics research: toward the development of a community genetics interventionLeader A, Mohanty S, Selvan P, Lum R, Giri V. Exploring Asian Indian and Pakistani views about cancer and participation in cancer genetics research: toward the development of a community genetics intervention. Journal Of Community Genetics 2017, 9: 27-35. PMID: 28660599, PMCID: PMC5752649, DOI: 10.1007/s12687-017-0312-x.
• Knowledge and understanding of genetic test results in men undergoing multigene testing for inherited prostate cancer.Giri V, Hegarty S, Obeid E, Hyatt C, Fang C, Leader A. Knowledge and understanding of genetic test results in men undergoing multigene testing for inherited prostate cancer. Journal Of Clinical Oncology 2017, 35: 1516-1516. DOI: 10.1200/jco.2017.35.15_suppl.1516.
• Insurance status and patterns of late diagnosis and cancer treatment: A population-based study.Lu-Yao G, He J, Giri V, Klassen A. Insurance status and patterns of late diagnosis and cancer treatment: A population-based study. Journal Of Clinical Oncology 2017, 35: e16553-e16553. DOI: 10.1200/jco.2017.35.15_suppl.e16553.
• Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic EvaluationGiri V, Obeid E, Gross L, Bealin L, Hyatt C, Hegarty S, Montgomery S, Forman A, Bingler R, Kelly W, Dicker A, Winheld S, Trabulsi E, Chen D, Lallas C, Allen B, Daly M, Gomella L. Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO Precision Oncology 2017, 1: 1-17. PMID: 34164591, PMCID: PMC8210976, DOI: 10.1200/po.16.00039.
• Abstract B01: Testing a multilevel risk prediction model in high risk men enrolled in a prostate cancer early detection programLynch S, Handorf E, Blackman E, Bealin L, Daniel S, Giri V, Obeid E, Ragin C, Daly M. Abstract B01: Testing a multilevel risk prediction model in high risk men enrolled in a prostate cancer early detection program. Cancer Epidemiology Biomarkers & Prevention 2017, 26: b01-b01. DOI: 10.1158/1538-7755.carisk16-b01.
• Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient CohortsTruong H, Hegarty S, Gomella L, Kelly W, Trabulsi E, Lallas C, Giri V. Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts. Journal Of Genetic Counseling 2017, 26: 548-555. PMID: 28101821, DOI: 10.1007/s10897-016-0020-4.
• Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring styleRoussi P, Miller S, Giri V, Obeid E, Wen K, Tagai E, Scarpato J, Gross L, Roy G. Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style. Journal Of Health Psychology 2016, 23: 1800-1809. PMID: 28810355, PMCID: PMC5561513, DOI: 10.1177/1359105316671188.
• Familial prostate cancerGiri V, Beebe-Dimmer J. Familial prostate cancer. Seminars In Oncology 2016, 43: 560-565. PMID: 27899188, PMCID: PMC6986340, DOI: 10.1053/j.seminoncol.2016.08.001.
• Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot StudyMyers R, Leader A, Censits J, Trabulsi E, Keith S, Petrich A, Quinn A, Den R, Hurwitz M, Lallas C, Hegarty S, Dicker A, Zeigler-Johnson C, Giri V, Ayaz H, Gomella L. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study. Journal Of Cancer Education 2016, 33: 180-185. PMID: 27418065, DOI: 10.1007/s13187-016-1073-7.
• Hereditary cancer syndromes and prostate cancer development among African American men: The importance of complete family cancer history.Obeid E, Hegarty S, Bealin L, Montgomery S, Gross L, Chen D, Giri V. Hereditary cancer syndromes and prostate cancer development among African American men: The importance of complete family cancer history. Journal Of Clinical Oncology 2016, 34: e16625-e16625. DOI: 10.1200/jco.2016.34.15_suppl.e16625.
• HOXB13 and other high penetrant genes for prostate cancerPilie P, Giri V, Cooney K. HOXB13 and other high penetrant genes for prostate cancer. Asian Journal Of Andrology 2016, 18: 530-532. PMID: 27034017, PMCID: PMC4955175, DOI: 10.4103/1008-682x.175785.
• PD13-07 CHARACTERIZATION OF UPPER TRACT UROTHELIAL CARCINOMA IN PATIENTS WITH CLINICAL SUSPICION OF LYNCH SYNDROMETruong H, Hegarty S, Hubosky S, Healy K, Hoffman-Censits J, Giri V. PD13-07 CHARACTERIZATION OF UPPER TRACT UROTHELIAL CARCINOMA IN PATIENTS WITH CLINICAL SUSPICION OF LYNCH SYNDROME. Journal Of Urology 2016, 195: e300. DOI: 10.1016/j.juro.2016.02.978.
• How I Do It: Genetic counseling and genetic testing for inherited prostate cancer.Giri V, Gross L, Gomella L, Hyatt C. How I Do It: Genetic counseling and genetic testing for inherited prostate cancer. Canadian Journal Of Urology 2016, 23: 8247-53. PMID: 27085833.
• Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancerNicolas E, Arora S, Zhou Y, Serebriiskii I, Andrake M, Handorf E, Bodian D, Vockley J, Dunbrack R, Ross E, Egleston B, Hall M, Golemis E, Giri V, Daly M. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. Oncotarget 2015, 6: 39614-39633. PMID: 26485759, PMCID: PMC4741850, DOI: 10.18632/oncotarget.5554.
• Abstract 537: Information-driven approaches to predicting familial risk for prostate cancerNicolas E, Zhou Y, Serebriiskii I, Andrake M, Handorf E, Dunbrack R, Giri V, Ross E, Golemis E, Hall M, Daly M. Abstract 537: Information-driven approaches to predicting familial risk for prostate cancer. 2015, 537-537. DOI: 10.1158/1538-7445.am2015-537.
• High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohortLiu J, Parajuli S, Blackman E, Gibbs D, Ellis A, Hull A, Beck J, Giri V, Iherjirka P, Khurana J, Ragin C. High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort. Head & Neck 2015, 38: e867-e872. PMID: 25962720, PMCID: PMC4643423, DOI: 10.1002/hed.24117.
• Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP).Hall M, Daly M, Ross E, Boyd J, Sanford E, Sun J, Stephens P, Liss D, Chen S, Miller V, Yelensky R, Giri V. Germline variants in cancer risk genes detected by NGS-based comprehensive tumor genomic profiling (CGP). Journal Of Clinical Oncology 2015, 33: 11084-11084. DOI: 10.1200/jco.2015.33.15_suppl.11084.
• Prevalence and race-based differences of suspected inherited renal cell cancer: Implications for genetic counseling referral and cancer susceptibility syndrome testing from a 10-year institutional experience.Giri V, Truong H, Trabulsi E, Kelly W, Lallas C, Gomella L. Prevalence and race-based differences of suspected inherited renal cell cancer: Implications for genetic counseling referral and cancer susceptibility syndrome testing from a 10-year institutional experience. Journal Of Clinical Oncology 2015, 33: e15606-e15606. DOI: 10.1200/jco.2015.33.15_suppl.e15606.
• Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH ProjectFleisher L, Davis S, Gross L, Bagden L, Zakrzewski D, González E, Kandadai V, Rusten C, Baskett J, Obeid E, Giri V. Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project. Journal Of Cancer Education 2015, 31: 191-197. PMID: 25971432, DOI: 10.1007/s13187-015-0854-8.
• Interest in genomic SNP testing for prostate cancer risk: a pilot surveyHall M, Ruth K, Chen D, Gross L, Giri V. Interest in genomic SNP testing for prostate cancer risk: a pilot survey. Hereditary Cancer In Clinical Practice 2015, 13: 11. PMID: 25874018, PMCID: PMC4396119, DOI: 10.1186/s13053-015-0032-3.
• Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.Carroll P, Parsons J, Andriole G, Bahnson R, Barocas D, Catalona W, Dahl D, Davis J, Epstein J, Etzioni R, Giri V, Hemstreet G, Kawachi M, Lange P, Loughlin K, Lowrance W, Maroni P, Mohler J, Morgan T, Nadler R, Poch M, Scales C, Shanefelt T, Vickers A, Wake R, Shead D, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. Journal Of The National Comprehensive Cancer Network 2014, 12: 1211-9; quiz 1219. PMID: 25190691, DOI: 10.6004/jnccn.2014.0120.
• Gene panel testing for inherited cancer risk.Hall M, Forman A, Pilarski R, Wiesner G, Giri V. Gene panel testing for inherited cancer risk. Journal Of The National Comprehensive Cancer Network 2014, 12: 1339-46. PMID: 25190699, DOI: 10.6004/jnccn.2014.0128.
• The clinical experience: Hereditary cancer testing by a 25-gene panel.Obeid E, Forman A, Hall M, Giri V, Montgomery S, Rainey K, Rybak C, Moyes K, Saam J, Daly M. The clinical experience: Hereditary cancer testing by a 25-gene panel. Journal Of Clinical Oncology 2014, 32: 1548-1548. DOI: 10.1200/jco.2014.32.15_suppl.1548.
• Interest in genomic SNP testing for prostate cancer risk.Giri V, Ruth K, Chen D, Gross L, Hall M. Interest in genomic SNP testing for prostate cancer risk. Journal Of Clinical Oncology 2014, 32: e12503-e12503. DOI: 10.1200/jco.2014.32.15_suppl.e12503.
• Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT StudyBancroft E, Page E, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster C, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans D, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney L, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick P, Bojesen A, Skytte A, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams W, Oosterwijk J, Blanco I, Salinas M, Cook J, Rosario D, Buys S, Conner T, Ausems M, Ong K, Hoffman J, Domchek S, Powers J, Teixeira M, Maia S, Foulkes W, Taherian N, Ruijs M, Enden A, Izatt L, Davidson R, Adank M, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman G, Zgajnar J, Tischkowitz M, Clowes V, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady A, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor D, Copakova L, Barwell J, Giri V, Murthy V, Nicolai N, Teo S, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, Collaborators T, Moss S, Eeles R. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology 2014, 66: 489-499. PMID: 24484606, PMCID: PMC4105321, DOI: 10.1016/j.eururo.2014.01.003.
• Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate CancerHandorf E, Crumpler N, Gross L, Giri V. Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer. Journal Of Genetic Counseling 2013, 23: 371-376. PMID: 24310616, PMCID: PMC4028414, DOI: 10.1007/s10897-013-9672-5.
• Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American menHughes L, Ruth K, Rebbeck T, Giri V. Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men. Prostate Cancer And Prostatic Diseases 2013, 16: 308-314. PMID: 24061634, PMCID: PMC3865712, DOI: 10.1038/pcan.2013.36.
• Genetic correction of PSA in men at high‐risk for PCAChang B, Hughes L, Chen D, Gross L, Ruth K, Giri V. Genetic correction of PSA in men at high‐risk for PCA. BJU International 2013, 113: e150-e156. PMID: 23937305, PMCID: PMC3830710, DOI: 10.1111/bju.12264.
• Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African DescentRebbeck T, Devesa S, Chang B, Bunker C, Cheng I, Cooney K, Eeles R, Fernandez P, Giri V, Gueye S, Haiman C, Henderson B, Heyns C, Hu J, Ingles S, Isaacs W, Jalloh M, John E, Kibel A, Kidd L, Layne P, Leach R, Neslund-Dudas C, Okobia M, Ostrander E, Park J, Patrick A, Phelan C, Ragin C, Roberts R, Rybicki B, Stanford J, Strom S, Thompson I, Witte J, Xu J, Yeboah E, Hsing A, Zeigler-Johnson C. Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent. Prostate Cancer 2013, 2013: 560857. PMID: 23476788, PMCID: PMC3583061, DOI: 10.1155/2013/560857.
• Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer among High-Risk Men Enrolled in Prostate Cancer Early DetectionHughes L, Zhu F, Ross E, Gross L, Uzzo R, Chen D, Viterbo R, Rebbeck T, Giri V. Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer among High-Risk Men Enrolled in Prostate Cancer Early Detection. Cancer Epidemiology Biomarkers & Prevention 2012, 21: 53-60. PMID: 22144497, PMCID: PMC3253936, DOI: 10.1158/1055-9965.epi-11-0727.
• Abstract B13: Lessons learned from implementing a prostate cancer risk assessment program for underserved high-risk men: The Prostate REACH ProjectFleisher L, Giri V, Davis S, Rusten C, Baskett J, Gross L, Bagden L, Zakrzewski D, González E, Kandadai V. Abstract B13: Lessons learned from implementing a prostate cancer risk assessment program for underserved high-risk men: The Prostate REACH Project. Cancer Epidemiology Biomarkers & Prevention 2011, 20: b13-b13. DOI: 10.1158/1055-9965.disp-11-b13.
• A Systematic Review of Replication Studies of Prostate Cancer Susceptibility Genetic Variants in High-Risk Men Originally Identified from Genome-Wide Association StudiesIshak M, Giri V. A Systematic Review of Replication Studies of Prostate Cancer Susceptibility Genetic Variants in High-Risk Men Originally Identified from Genome-Wide Association Studies. Cancer Epidemiology Biomarkers & Prevention 2011, 20: 1599-1610. PMID: 21715604, DOI: 10.1158/1055-9965.epi-11-0312.
• Rates and predictors of colorectal cancer screening by race among motivated men participating in a prostate cancer risk assessment programHall M, Ruth K, Giri V. Rates and predictors of colorectal cancer screening by race among motivated men participating in a prostate cancer risk assessment program. Cancer 2011, 118: 478-484. PMID: 21751189, PMCID: PMC3195866, DOI: 10.1002/cncr.26315.
• Familial Clustering of Sporadic Kidney Cancer: Insufficient Evidence to Recommend Routine Screening in Unaffected KinSmaldone M, Giri V, Uzzo R. Familial Clustering of Sporadic Kidney Cancer: Insufficient Evidence to Recommend Routine Screening in Unaffected Kin. European Urology 2011, 60: 994-995. PMID: 21741161, DOI: 10.1016/j.eururo.2011.06.026.
• Abstract 1820: Genetic polymorphisms in microRNA target sites in IL-16 and IL-18 may be informative of time to prostate cancer diagnosis in African American menHughes L, Ruth K, Giri V. Abstract 1820: Genetic polymorphisms in microRNA target sites in IL-16 and IL-18 may be informative of time to prostate cancer diagnosis in African American men. Cancer Research 2011, 71: 1820-1820. DOI: 10.1158/1538-7445.am2011-1820.
• Validation of Genome-Wide Prostate Cancer Associations in Men of African DescentChang B, Spangler E, Gallagher S, Haiman C, Henderson B, Isaacs W, Benford M, Kidd L, Cooney K, Strom S, Ingles S, Stern M, Corral R, Joshi A, Xu J, Giri V, Rybicki B, Neslund-Dudas C, Kibel A, Thompson I, Leach R, Ostrander E, Stanford J, Witte J, Casey G, Eeles R, Hsing A, Chanock S, Hu J, John E, Park J, Stefflova K, Zeigler-Johnson C, Rebbeck T. Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent. Cancer Epidemiology Biomarkers & Prevention 2011, 20: 23-32. PMID: 21071540, PMCID: PMC3110616, DOI: 10.1158/1055-9965.epi-10-0698.
• Abstract B104: Disparities in colorectal cancer screening among motivated men participating in a prostate cancer risk assessment programHall M, Ruth K, Giri V. Abstract B104: Disparities in colorectal cancer screening among motivated men participating in a prostate cancer risk assessment program. Cancer Epidemiology Biomarkers & Prevention 2010, 19: b104-b104. DOI: 10.1158/1055-9965.disp-10-b104.
• Abstract B11: The Lincoln University-Fox Chase Partnership in cancer research and training: Summer internship programBerger T, Louden D, Chikwem J, Fleisher L, Murphy M, Fang C, Clapper M, Wen K, Gaither-Hardy D, Baskerville K, Mechanic K, Burger R, Miller B, Hopper-Borge E, Giri V, Safford S, Swinton D, Beck J. Abstract B11: The Lincoln University-Fox Chase Partnership in cancer research and training: Summer internship program. Cancer Epidemiology Biomarkers & Prevention 2010, 19: b11-b11. DOI: 10.1158/1055-9965.disp-10-b11.
• Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160ValGiri V, Ruth K, Hughes L, Uzzo R, Chen D, Boorjian S, Viterbo R, Rebbeck T. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val. BJU International 2010, 107: 466-470. PMID: 20735386, PMCID: PMC3052292, DOI: 10.1111/j.1464-410x.2010.09522.x.
• NCCN clinical practice guidelines in oncology: prostate cancer early detection.Kawachi M, Bahnson R, Barry M, Busby J, Carroll P, Carter H, Catalona W, Cookson M, Epstein J, Etzioni R, Giri V, Hemstreet G, Howe R, Lange P, Lilja H, Loughlin K, Mohler J, Moul J, Nadler R, Patterson S, Presti J, Stroup A, Wake R, Wei J. NCCN clinical practice guidelines in oncology: prostate cancer early detection. Journal Of The National Comprehensive Cancer Network 2010, 8: 240-62. PMID: 20141680, DOI: 10.6004/jnccn.2010.0016.
• Abstract A9: Genetic polymorphisms in the vitamin D receptor gene and androgen pathway gene SRD5A2 may be informative of prostate cancer risk in African American men undergoing prostate cancer screeningHughes L, Ruth K, Giri V. Abstract A9: Genetic polymorphisms in the vitamin D receptor gene and androgen pathway gene SRD5A2 may be informative of prostate cancer risk in African American men undergoing prostate cancer screening. Cancer Prevention Research 2010, 3: a9-a9. DOI: 10.1158/1940-6207.prev-09-a9.
• Prostate Cancer Early Detection Program Recruitment Methods and Show Rates in Men at High RiskGiri V, Coups E, Ruth K, Goplerud J, Raysor S, Kim T, Bagden L, Mastalski K, Zakrzewski D, Leimkuhler S, Watkins-Bruner D. Prostate Cancer Early Detection Program Recruitment Methods and Show Rates in Men at High Risk. Journal Of Urology 2009, 182: 2212-2218. PMID: 19758657, PMCID: PMC2760660, DOI: 10.1016/j.juro.2009.07.021.
• Genetic polymorphisms and early-onset prostate cancer: a real potential to personalize prostate cancer screening?Hughes L, Giri V. Genetic polymorphisms and early-onset prostate cancer: a real potential to personalize prostate cancer screening? Future Oncology 2009, 5: 923-926. PMID: 19792959, DOI: 10.2217/fon.09.75.
• Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening populationKaplan D, Boorjian S, Ruth K, Egleston B, Chen D, Viterbo R, Uzzo R, Buyyounouski M, Raysor S, Giri V. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population. BJU International 2009, 105: 334-337. PMID: 19709072, PMCID: PMC2809782, DOI: 10.1111/j.1464-410x.2009.08793.x.
• Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancerTseng M, Giri V, Watkins-Bruner D, Giovannucci E. Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer. Cancer Causes & Control 2009, 20: 1947-1954. PMID: 19578936, PMCID: PMC2895954, DOI: 10.1007/s10552-009-9389-9.
• Prevalence and correlates of vitamin D status in African American menTseng M, Giri V, Bruner D, Giovannucci E. Prevalence and correlates of vitamin D status in African American men. BMC Public Health 2009, 9: 191. PMID: 19534831, PMCID: PMC2708155, DOI: 10.1186/1471-2458-9-191.
• Met160Val TMPRSS2 gene polymorphism and early onset prostate cancer in high-risk menGiri V, Hughes L, Ruth K. Met160Val TMPRSS2 gene polymorphism and early onset prostate cancer in high-risk men. Journal Of Clinical Oncology 2009, 27: 5000-5000. DOI: 10.1200/jco.2009.27.15_suppl.5000.
• Dose intensity of cisplatin and gemcitabine (CG) for muscle invasive urothelial bladder cancer (MIUBC) in the neoadjuvant versus adjuvant settings: The Fox Chase Cancer Center (FCCC) experienceHoffman-Censits J, Wong Y, Li T, Boorjian S, Giri V, Uzzo R, Greenberg R, Hudes G, Chen D. Dose intensity of cisplatin and gemcitabine (CG) for muscle invasive urothelial bladder cancer (MIUBC) in the neoadjuvant versus adjuvant settings: The Fox Chase Cancer Center (FCCC) experience. Journal Of Clinical Oncology 2009, 27: e16012-e16012. DOI: 10.1200/jco.2009.27.15_suppl.e16012.
• Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk MenGiri V, Egleston B, Ruth K, Uzzo R, Chen D, Buyyounouski M, Raysor S, Hooker S, Torres J, Ramike T, Mastalski K, Kim T, Kittles R. Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men. Cancer Prevention Research 2009, 2: 244-250. PMID: 19240249, PMCID: PMC2652509, DOI: 10.1158/1940-6207.capr-08-0150.
• Abstract B54: Prostate cancer screening characteristics in high-risk men with genetic risk markers at 8q and 17qWilliams K, Ruth K, Hughes L, Giri V. Abstract B54: Prostate cancer screening characteristics in high-risk men with genetic risk markers at 8q and 17q. Cancer Prevention Research 2008, 1: b54-b54. DOI: 10.1158/1940-6207.prev-08-b54.
• Substantial family history of prostate cancer in black men recruited for prostate cancer screeningMastalski K, Coups E, Ruth K, Raysor S, Giri V. Substantial family history of prostate cancer in black men recruited for prostate cancer screening. Cancer 2008, 113: 2559-2564. PMID: 18816608, PMCID: PMC2626163, DOI: 10.1002/cncr.23862.
• Using Focus Groups to Adapt Ethnically Appropriate, Information-Seeking and Recruitment Messages for a Prostate Cancer Screening Program for Men at High RiskBryan C, Wetmore-Arkader L, Calvano T, Deatrick J, Giri V, Bruner D. Using Focus Groups to Adapt Ethnically Appropriate, Information-Seeking and Recruitment Messages for a Prostate Cancer Screening Program for Men at High Risk. Journal Of The National Medical Association 2008, 100: 674-682. PMID: 18595569, PMCID: PMC2700360, DOI: 10.1016/s0027-9684(15)31340-7.
• Prostate Cancer Risk Assessment Program: A 10-Year Update of Cancer DetectionGiri V, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg S, Uzzo R, Hanks G, Godwin A, Chen D, Gordon R, Cescon T, Raysor S, Watkins-Bruner D. Prostate Cancer Risk Assessment Program: A 10-Year Update of Cancer Detection. Journal Of Urology 2007, 178: 1920-1924. PMID: 17868726, DOI: 10.1016/j.juro.2007.07.010.
• EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressorHwang C, Giri V, Wilkinson J, Wright C, Wilkinson A, Cooney K, Duckett C. EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor. Breast Cancer Research And Treatment 2007, 107: 235-242. PMID: 17453341, DOI: 10.1007/s10549-007-9542-7.
• Causes of Preventable Visual Loss in Type 2 Diabetes MellitusHayward R, Cowan C, Giri V, Lawrence M, Makki F. Causes of Preventable Visual Loss in Type 2 Diabetes Mellitus. Journal Of General Internal Medicine 2005, 20: 467-469. PMID: 15963174, PMCID: PMC1490102, DOI: 10.1111/j.1525-1497.2005.40073.x.
• Association between Agent Orange and prostate cancer: a pilot case-control studyGiri V, Cassidy A, Beebe-Dimmer J, Ellis L, Smith D, Bock C, Cooney K. Association between Agent Orange and prostate cancer: a pilot case-control study. Urology 2004, 63: 757-760. PMID: 15072895, DOI: 10.1016/j.urology.2003.11.044.
• Genome‐wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1Lange E, Gillanders E, Davis C, Brown W, Campbell J, Jones M, Gildea D, Riedesel E, Albertus J, Freas‐Lutz D, Markey C, Giri V, Dimmer J, Montie J, Trent J, Cooney K. Genome‐wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. The Prostate 2003, 57: 326-334. PMID: 14601029, DOI: 10.1002/pros.10307.